Trimetazidine in coronary heart disease patients: mechanism of action and controlled trials’ results

Metabolic cardioprotection is an important part of treating patients with coronary heart disease (CHD). The most widely used drug in this group is trimetazidine. Its mechanism of action is based on fatty acids metabolism inhibition, glucose oxidation activation, intracellular ATP deficit prevention....

Full description

Bibliographic Details

Published in:	Кардиоваскулярная терапия и профилактика
Main Authors:	L. V. Kremneva, O. V. Abaturova, S. V. Shalaev
Format:	Article
Language:	Russian
Published:	«SILICEA-POLIGRAF» LLC 2005-04-01
Subjects:	metabolic cardioprotection trimetazidine stable angina myocardial infarction heart failure myocardial revascularization
Online Access:	https://cardiovascular.elpub.ru/jour/article/view/938